Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF)

Thursday, 19 September 2019, 13:15 - 14:15, Joslin Hall

Chair: N. Sattar, UK

M.N. Kosiborod, US: Background, design and results of DAPA-HF - key cardiovascular outcomes

S. Inzucchi, US: DAPA-HF: Metabolic and safety data and implications for the diabetologist